Medunik USA Expands Medicaid Coverage for Pheburane in Rare Disease Treatment Access Initiative
Key Insights
Medunik USA has strengthened Pheburane® (sodium phenylbutyrate) coverage under Medicaid programs, with 19 states now offering preferred coverage and 29 states providing limited or no restrictions.
The expansion addresses treatment disparities for urea cycle disorders, which affect one in 35,000 Americans and can cause life-threatening ammonia buildup in the bloodstream.
Pheburane® is now reimbursed under commercial insurance plans reaching approximately 80% of the commercially insured US population, supported by comprehensive patient assistance programs.
Medunik USA announced significant expansion of Medicaid coverage for Pheburane® (sodium phenylbutyrate), marking a crucial step forward in addressing treatment disparities for patients with rare urea cycle disorders (UCDs). The specialty pharmaceutical company, part of Duchesnay Pharmaceutical Group (search), has secured preferred Medicaid coverage in 19 states, while 29 additional states now offer the therapy under Medicaid programs with limited or no restrictions.
The coverage expansion comes as approximately one in 35,000 Americans suffer from UCDs of varying severity levels, representing a significant unmet medical need in the rare disease community. Pheburane® is also reimbursed under commercial insurance plans that reach approximately 80% of the commercially insured US population.
Enhanced Patient Access Through Comprehensive Support
"Convinced that patients suffering from rare diseases are no less deserving of effective treatment options than those suffering from more common conditions, we strive to ensure that Americans living with UCDs have timely and affordable access to this therapy," said Tanya Carro, Executive Vice President, U.S. Entities at Medunik USA.
The company has developed the UNIK Support Program to provide comprehensive assistance throughout patients' treatment journeys. The program includes clinical coordinator outreach providing personalized support, copay and patient assistance programs enabling eligible patients to pay as little as $0, mail-order pharmacy services through two national specialty pharmacies, and a Quick Start & Bridge Program offering immediate treatment access while insurance approvals are processed.
Understanding Urea Cycle Disorders
UCDs are rare genetic disorders that disrupt the body's ability to eliminate toxic ammonia from the blood and convert it to urea for excretion. When this process fails, dangerous levels of ammonia can accumulate in the bloodstream, posing particular risks to the central nervous system. The disorders can cause catastrophic illness in newborns within 36 to 48 hours of birth, often after infants appear normal and may have been discharged from the hospital before symptoms develop.
These conditions require lifelong monitoring and treatment, with ammonia serving as the key diagnostic marker for UCDs. The toxic effects of elevated ammonia levels can be fatal if not properly managed.
Pheburane® Therapeutic Profile
Pheburane® represents an innovative formulation of sodium phenylbutyrate, consisting of very small coated oral pellets approximately the size of sugar crystals. The FDA-approved therapy serves as adjunctive treatment alongside dietary management for chronic management of adult and pediatric patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).
The taste-masked oral formulation addresses palatability concerns common with rare disease treatments. However, Pheburane® is not indicated for treating acute hyperammonemia episodes, which require emergency medical intervention. The most common side effects associated with sodium phenylbutyrate include menstrual dysfunction, decreased appetite, body odor, and taste aversion.
Strategic Market Context
The coverage expansion occurs amid recent availability of generic alternatives for commonly prescribed UCD treatments, positioning Pheburane®'s comprehensive patient support services as a key differentiator. Medunik USA's approach emphasizes not just medication access but holistic patient care through its specialized support infrastructure.
Developed by Lucane Pharma (search) and distributed exclusively in the United States through Medunik USA, Pheburane® represents part of the broader rare disease treatment portfolio offered by Duchesnay Pharmaceutical Group (search). The parent company recently received recognition as winner of the 2024 Life Sciences Innovation Award by ADRIQ, acknowledging its commitment to pharmaceutical innovation and healthy workplace culture.